Aragen Life Sciences elevates Pavan Kumar Kamarajugadda to Senior Director

FDA fast-tracks Roche’s giredestrant review as data signal potential shift in early breast cancer care

The filing is backed by Phase III data from the lidERA Breast Cancer study

Cancer drug “iza-bren” posts strong Phase 3 wins across multiple tumor types

The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials

Servier to acquire Edgewise muscular dystrophy business in $2.65 billion deal

The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments

Omnix Medical doses first patients in phase II trial of antimicrobial lead compound OMN6

First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept

CORONA Remedies receives EU-GMP certification for hormone facility

Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets

Marksans Pharma to acquire Netherlands-based QliniQ

Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets

Moderna and Merck’s mRNA cancer vax combo shows 5-year survival in melanoma trial

An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary

BioNTech and Bristol Myers Squibb drug shows strong early signal in lung cancer trial

The safety profile was described as manageable, though not without notable toxicities

Ebola vax on the anvil?

CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate